Dr Luke Grzeskowiak is a NHMRC Early Career Research Fellow in the Robinson Research Institute at the University of Adelaide and a Senior Pharmacist, Flinders Women and Children, Flinders Medical Centre, SA Pharmacy.
Luke’s clinical and research ambitions are to enhance maternal and newborn health outcomes through supporting quality use of medicines and the development and promotion of more efficacious, safer, and personalised pharmacotherapy approaches. He completed his PhD in 2012 which focused on evaluating different approaches towards investigating the long-term effects of medication use during pregnancy. His current clinical/research interests include perinatal pharmacoepidemiology, obstetric and neonatal pharmacology, medication safety, and evidence-based medicine. To date, he has more than 50 peer-reviewed publications, has given more than 60 presentations at national and international conferences, and received more than $350,000 in research funding.
Luke is passionate about clinical education, training, and research, and the roles that pharmacists play in sustaining a continual improvement culture. He is a Fellow of the Society of Hospital Pharmacists of Australia (SHPA) and is currently serving in the role as treasurer in his 9th year on the SHPA SA/NT Branch Committee. He is also a member of the SHPA National Educational Reference Group and steering committee for the SHPA National Translational Research Collaborative (NTRC), in addition to being the founder and organiser of the SHPA Practice-Based Research Seminar.
The last decade has seen a tremendous growth in the use of antidepressants in the general population, including pregnancy, bringing with it a great deal of concern relating to the potential harms they may pose to mothers and their babies. Such concerns are exemplified through the often alarmist, attention hungry, media headlines and community opinion, leading to a high proportion of women who stop taking their antidepressants during pregnancy.
This presentation will look at the latest evidence regarding the potential long-term effects of antidepressant use in pregnancy on child developmental outcomes with a focus on evaluating how the current evidence, and that from future studies, can be utilised to generate evidence-based recommendations and guide future clinical practice.